BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Leveraging Strategic Board Appointment to Execute Visionary Strategy

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently announced its appointment of Jerry White as an advisor to the company. White has been recognized for his efforts in engaging large audiences to power global movements and is a recognized leader of the International Campaign to Ban Landmines and a co-recipient of the 1997 Nobel Peace Prize. Given his expertise, ambition and successful track record, White is an excellent addition to the company’s advisory board as it focusses on achieving strategic goals while working towards its overall vision. “Never shying away from audacious goals, driving transformational global movements, asking the toughest of questions, and translating them to strategy — this is what Jerry brings and why I am so thrilled to welcome him to the advisory board at MINDCURE. It’s an honor to welcome a truly noble and humane impact strategist to our advisory board,” said Kelsey Ramsden, president and CEO of Mind Cure. “I look forward to working with Jerry on our visionary strategy to build mental wealth worldwide.”

To view the full article, visit https://ibn.fm/Nhplc

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to…

7 hours ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to…

3 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease 

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the…

4 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons…

4 days ago

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet…

4 days ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent…

5 days ago